Lenalidomide as Second-line Treatment for Advanced Hepatocellular Carcinoma (HCC): a Phase II Clinical Trial.
Phase of Trial: Phase II
Latest Information Update: 14 Feb 2017
At a glance
- Drugs Lenalidomide (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 07 Feb 2017 Status changed from active, no longer recruiting to completed.
- 11 Oct 2016 Results of a biomarker and efficacy analysis presented at the 41st European Society for Medical Oncology Congress.
- 20 Jul 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Oct 2016.